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Background and Objective. EBUS-TBNA has revolutionized the diagnostic approach to thoracic diseases from a surgical to
minimally invasive procedure. In non small-cell lung cancer (NCSLC) patients, EBUS-TBNA is able to dictate the consecutive
therapy both for early and advanced stages, providing pathological diagnosis, mediastinal staging, and even adequate specimens
for molecular analysis. +is study reports on the ability of EBUS-TBNA to make diﬀerent diagnoses and dictates the consecutive
therapy in a large cohort of patients presenting diﬀerent thoracic diseases.Methods. All procedures performed from January 2012
to September 2016 were reviewed. Five groups of patients were created according to the main indications for the procedure. Group
1: lung cancer staging; Group 2: pathological diagnosis in advanced stage lung cancer; Group 3: lymphadenopathy in previous
malignancies; Group 4: pulmonary lesions; Group 5: unknown origin lymphadenopathy. In each group, the diagnostic yield of the
procedure was analysed. Non malignant diagnosis at EBUS-TBNA was conﬁrmed by a surgical procedure or clinical and ra-
diological follow-up. Results. 1891 patients were included in the analysis. Sensitivity, negative predictive value, and diagnostic
accuracy in each group were 90.7%, 79.4%, and 93.1% in Group 1; 98.5%, 50%, and 98.5% in Group 2; 92.4%, 85.1%, and 94.7% in
Group 3; 90.9%, 51.0%, and 91.7% in Group 4; and 25%, 83.3%, and 84.2% in Group 5. Overall sensitivity, negative predictive value,
and accuracy were 91.7%, 78.5%, and 93.6%, respectively. Conclusions. EBUS-TBNA is the best approach for invasive mediastinal
investigation, conﬁrming its strategic role and high accuracy in thoracic oncology.
1. Introduction
Mediastinal adenopathy has always been assessed by ra-
diological imaging such as computed tomography (CT) and
positron emission tomography (PET), with high sensitivity
but a low diagnostic accuracy for the purposes of correct
clinical decision-making [1]. To date, mediastinoscopy has
been considered the gold standard for diagnosis and me-
diastinal staging with high sensitivity and accuracy, but the
procedure has been progressively underused due to its high
invasiveness, risk of complications, and the need to be
performed in experienced centres [2].
In the early 2000’s, a minimally invasive convex probe
endobronchial ultrasound (EBUS) procedure able to per-
form real-time transbronchial needle aspiration (TBNA)
was described with high accuracy for mediastinal and hilar
lymph node staging [3]. Since then, EBUS-TBNA has grad-
ually changed the way mediastinal staging is performed and
rapidly improved its value with new indications in lung cancer
management, becoming the standard of care [4].
In thoracic oncology, EBUS-TBNA has revolutionized
the diagnostic approach to lung cancer and other neoplasms
from a surgical to minimally invasive procedure. Especially
in non small-cell lung cancer (NCSLC), EBUS-TBNA is able
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to dictate the consecutive therapy both for early and ad-
vanced stages, providing pathological diagnosis, mediastinal
staging, and even adequate specimens for molecular analysis
[5]. In addition, EBUS-TBNA has been described in diﬀerent
clinical scenarios, particularly for the diagnosis and deﬁ-
nition of granulomatosis such as sarcoidosis [6] and tu-
berculosis [7] and for pathological assessment of mediastinal
and hilar recurrences from previous malignancies [8, 9].
+is study reports the largest published experience in the
use of EBUS-TBNA in a high-volume thoracic oncology
institution. We aimed to describe the utility and diagnostic
yield of EBUS-TBNA in diﬀerent clinical scenarios in
thoracic diseases, dividing our series into ﬁve diﬀerent
groups according to the main indication for the procedure
(Group 1: lung cancer staging, Group 2: pathological di-
agnosis in advanced stage lung cancer, Group 3: lymph-
adenopathy in previous malignancies, Group 4: pulmonary
lesions, and Group 5: unknown origin lymphadenopathy)
and reporting our results in terms of sensitivity, negative
predictive value, and diagnostic accuracy.
2. Methods
+is single-centre retrospective study with a prospective
follow-up was approved by the Institutional Review Board
and the individual consent was obtained.
From January 2012 to September 2016, 1958 EBUS-
TBNA procedures were performed at our institution. +e
indications for EBUS-TBNA, lymph node stations, number
of lymph nodes sampled, cytological results, and cancer cell
type were obtained for the analysis. To better standardize the
series, diﬀerent groups of patients were deﬁned according to
the indication for the procedure.
Group 1 included patients referred for EBUS-TBNA for
mediastinal staging in potentially operable lung cancer and
patients with mediastinal involvement but no evidence of
distant metastasis. Patients with proven or suspected NSCLC
were included, and pathological cell type was performed in
the same procedure. According to our institutional protocol,
suspect lymph nodes were deﬁned as lymph nodes with
a pathological PET scan uptake and/or enlarged lymph
nodes with more than 1 cm in the short axis at the CT scan.
Group 2 included patients with metastatic and/or bulky
mediastinal disease referred for EBUS-TBNA for patho-
logical diagnosis and molecular mutational analysis for
targeted therapy; Group 3 included patients with a previous
(thoracic or extrathoracic) malignancy who developed
mediastinal and hilar lymphadenopathies suspected for
recurrence; Group 4 included patients who underwent
EBUS-TBNA for primary tissue sampling in pulmonary
lesions (paratracheal or peribronchial); and Group 5 in-
cluded patients withmediastinal and hilar lymphadenopathy
of unknown origin with no history of malignancy. Di-
agnostic sensitivity, accuracy, and negative predictive value
were calculated according to standard deﬁnitions. Sensitivity
was calculated for the diagnosis of malignancy.
EBUS-TBNA samples were considered diagnostic when
a deﬁnitive diagnosis was obtained. Lymph node samples
negative for malignancy underwent surgical conﬁrmation
(mediastinoscopy or VATS) or clinical and radiological
follow-up (at least 12 months of follow-up). Patients with
loss of follow-up were excluded.
EBUS-TBNA samples were considered false negative
when surgery changed the ﬁnal diagnosis, or there was
clinical and radiological progression of the disease during
follow-up. EBUS-TBNA samples insuﬃcient or inadequate
for diagnosis were considered false negative in the calcu-
lation of diagnostic accuracy. Patients without a speciﬁc
diagnosis at EBUS-TBNA (benign or malignant) but a de-
ﬁnitive non-malignant diagnosis at mediastinoscopy were
considered false negative.
During EBUS-TBNA procedures, all lymphadenopathies
with increased PET scan pathological uptake were sampled
in patients with a non-malignant diagnosis at rapid on-site
evaluation (ROSE), and at least one mediastinal and two hilar
stations were sampled when ROSE was negative for tumour
cells and suspected for lymphadenitis granulomatosis.
Patients with negative EBUS-TBNA samples were re-
ferred for conﬁrmatory surgical procedures after a multidis-
ciplinary teamdiscussionwith thoracic surgeons, pulmonologists,
radiologists, oncologists, and radiotherapists when lymphade-
nopathies were considered highly suspicious for recurrence based
on CT and/or PET scan characteristics.
2.1. EBUS-TBNA Technical Aspects. EBUS-TBNA pro-
cedures were performed under local anaesthesia (1% lido-
caine), and moderate sedation was provided by an
anaesthesiologist with spontaneous ventilation. +e same
team of interventional pulmonologists using a convex probe
(EBUS Convex Probe BF-UC180F; Olympus) and a dedi-
cated ultrasound processor (EU-ME1; Olympus) performed
all procedures. All EBUS-TBNA specimens were collected
with a 22 gauge dedicated needle (Vizishot NA-201SX-4022;
Olympus).
A very small amount of the aspirated material was
pushed out by the internal stylet and smeared onto glass
slides for immediate on-site evaluation (ROSE). Mirror
slides were alcohol-ﬁxed for posterior evaluation. Air-dried
smears were immediately stained with a modiﬁed May-
Gru¨nwald Giemsa stain (MGG Quick Stain; Bio-Optica,
Milan, Italy) and evaluated by the cytopathologist to con-
ﬁrm adequate tumour cells and/or lymph node material. +e
remaining aspirate and other needle passages (at least three
needle passages each station) were ﬁxed in a formalin so-
lution for cell block processing and histological evaluation.
Alcohol-ﬁxed smears were stained with Papanicolaou and
haematoxylin-eosin stains.
3. Results
Out of 1958 patients, 1891 were included in the study. Sixty-
seven patients were excluded from statistical analysis due to
loss of follow-up with the impossibility to conﬁrm the
negativity of lymph node samples. Patients’ mean age was 65
years (range: 20–92), 1197 (63.3%) were men.
+e leading indication for EBUS-TBNA at our in-
stitution was lung cancer staging in 728 (38.5%) patients
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followed by pathological diagnosis and mutational status in
advanced stage lung cancer in 401 (21.2%) patients,
lymphadenopathy in previous malignancies in 320 (17%)
cases, diagnosis of pulmonary lesions in 290 (15.3%), and
diagnosis of unknown origin lymphadenopathy in 152 (8%)
patients. Patient characteristics and indications for the
procedures are reported in Table 1.
A total of 2298 lymph node stations were sampled: 1003
superior mediastinal: 2 high upper station #1, 56 station #2R,
8 station #2L, 740 station #4R, and 197 station #4L; 789
subcarinal station #7; 506 N1 nodes: 57 hilar (37 station #10R
and 20 station #10L), 365 interlobar (191 station #11R and
174 station #11L), 83 lobar (53 station #12R and 30 station
#12L), and 1 segmental station #13L. Lymph node sampled
locations and number of lymph nodes are listed in Table 2.
Cytological diagnoses were adenocarcinoma in 692
patients, squamous cell carcinoma in 216, neuroendocrine
tumours in 143 (102 small-cell lung cancer (SCLC), 19 large-
cell neuroendocrine tumours, 9 mixed large- and small-cell
neuroendocrine tumours, 10 typical carcinoids, 3 atypical
carcinoids), 154 metastases from extrathoracic malignancy,
65 poorly diﬀerentiated NSCLC, 24 lymphoproliferative
disorders, 34 other malignancies (1 thymoma, 8 mesothelioma,
3 adenoid cystic carcinoma, 6 mixed tumours, 9 poorly dif-
ferentiated epithelial tumours of unknown origin, 1 sarcoma,
and 3 sarcomatoid carcinomas), 100 lymphadenitis gran-
ulomatosis (97 sarcoid-like reaction and 3 tuberculosis), 316
normal/reactive lymph nodes, and 28 other non-neoplastic
diagnoses (Table 3).
Overall sensitivity, negative predictive value, and diagnostic
accuracy were 91.7% (95% CI: 90.1–93.0), 78.5% (95% CI:
74.9–81.7), and 93.6% (95% CI: 92.4–94.6), respectively.
3.1. Group 1: Lung Cancer Staging. Out of 728 (60.2%) pa-
tients, 438 underwent EBUS-TBNA for mediastinal staging
and the diagnosis of the cell-type tumour in the same
procedure, and 244 (33.5%) had a previous pathological
diagnosis of NSCLC, and EBUS-TBNA was performed for
complete mediastinal staging, and in 46 (6.3%) patients,
EBUS-TBNA was performed for restaging the mediastinum
after induction chemotherapy for stage IIIA (pN2) NSCLC.
In this group, EBUS-TBNAwas diagnostic for malignancy in
485 (66.6%) patients, and a mean of 1, 5 lymph nodes per
patient was biopsied. In 187 (25.7%) cases, EBUS-TBNA
revealed normal or reactive lymph node samples, and in six
(0.8%), EBUS-TBNA revealed a granulomatous reaction in
ﬁve cases of sarcoid-like reaction compatible with sar-
coidosis and one case of necrotizing granulomatosis with
a positive culture for Mycobacterium tuberculosis.
Malignant diagnoses included 278 adenocarcinoma, 102
squamous cell carcinoma, 55 neuroendocrine, 27 poorly dif-
ferentiated nonsmall-cell lung cancer, and 23 othermalignancies
(6 metastasis from a nonthoracic malignancy, 5 lymphoma, 4
mesothelioma, 1 carcinosarcoma, 1 mixed squamous cell and
adenocarcinoma, and 6 undiﬀerentiated epithelioid neoplasms).
Fourty-six patients underwent EBUS-TBNA for restaging
the mediastinum after neoadjuvant chemotherapy. +ere
were 16 out of 46 (34.8%) positive for malignancy and 6 (13%)
false negative cases. From false negative cases, four patients
received chemotherapy andmediastinal radiotherapy and two
patients’ neoadjuvant chemotherapy. Sensitivity, negative
predictive value, and diagnostic accuracy in this subgroup of
patients were 66.7% (95% CI: 45.4–82.8), 78.1% (95% CI:
61.2–89), and 84.8% (95% CI: 71.8–92.4), respectively.
Among 193 patients with a nonmalignant diagnosis at
EBUS-TBNA, 146 underwent surgical procedures for pri-
mary tumours conﬁrming the negativity of lymph node
samples, and 47 patients were excluded from surgery for
clinical reasons and underwent a mean of 17.9 month’s
clinical and radiological follow-up. In this group, there were
50 (6.9%) false-negative samples. Sensitivity, negative pre-
dictive value, and diagnostic accuracy in the staging group
were 90.7% (95% CI: 87.9–92.8), 79.4% (95% CI: 73.9–84.0),
and 93.1% (95% CI: 91.1–94.8), respectively.
3.2. Group 2: Pathological Diagnosis andMutational Status in
Advanced Stage Lung Cancer. +is group comprised 401
patients. In 344 (85.8%) patients, EBUS-TBNA was performed
Table 1: Patient characteristics and indications for EBUS-TBNA.
Variable N
° or median
(range)
Patients (total) 1891
Sex
Male 1197
Female 694
Age (years) 65 (20–92)
Indications for EBUS-TBNA
Lung cancer staging 728
Pathological diagnosis and mutational
status in advanced stage lung cancer 401
Lymphadenopathy in previous
malignancy 320
Diagnosis of pulmonary lesions 290
Unknown origin lymphadenopathy 152
Table 2: Lymph node stations sampled by EBUS-TBNA in 1569
patients∗.
Stations Right Left
Total 2298
Superior mediastinal 1003
Highest mediastinal (station 1) 1 1
Upper paratracheal (2R/2L) 56 8
Lower paratracheal (4R/4L) 740 197
Inferior mediastinal
Subcarinal (7) 789
N1 nodes 506
Hilar (10R/10L) 37 20
Interlobar (11R/11L) 191 174
Lobar (12R/12L) 53 30
Segmental (13R/13L) 0 1∗Tissue sampling of pulmonary lesions in 322 cases.
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for the ﬁrst cell type diagnosis in stages IIIB and IV lung cancer,
and in 57 (14.2%) patients, the procedure was performed after
an initial established pathological diagnosis for tissue sampling
for molecular analysis including the epidermal growth factor
(EGFR)mutational proﬁle, anaplastic lymphoma kinase (ALK)
fusion genes, and mesenchymal-epithelial transition (MET)
protooncogene ampliﬁcation. Sensitivity, negative predictive
value, and diagnostic accuracy in this group were 98.5% (95%
CI: 96.7–99.3), 50% (95% CI: 25.4–74.6), and 98.5% (95% CI:
96.8–99.3), respectively.
3.3.Group3: Lymphadenopathy inPreviousMalignancy. Out
of 320 (59.4%) patients, 190 had a diagnosis of a recurrence
of a previous tumour and 113 (35.3%) had a diﬀerent di-
agnosis from the previous tumour. +ere were 17 (5.3%)
false negative cases. In 97 patients, EBUS-TBNA revealed
a deﬁnitive nonmalignant diagnosis, and 35 patients had
evidence of a granulomatosis disease. Twenty-two out of 114
(19.3%) patients with nonmalignant diagnoses at EBUS-
TBNA underwent mediastinoscopy or other surgical pro-
cedures to conﬁrm the negativity of EBUS-TBNA diagnosis,
and 92 (80.7%) patients underwent clinical and radiological
median follow-up of 17 months. Sensitivity, negative pre-
dictive value, and diagnostic accuracy were 92.4% (95% CI:
88.1–95.2), 85.1% (95% CI: 77.4–90.5), and 94.7% (95% CI:
91.7–96.7), respectively.
3.4. Group 4: Pulmonary Lesions. EBUS-TBNA was di-
agnostic for malignancy in 241 out of 290 (83.1%) cases.
Cytological diagnoses were 10 lymphoproliferative disor-
ders, 95 adenocarcinomas, 55 squamous cell carcinoma, 25
neuroendocrine tumours, 29 metastasis from other neo-
plasms, 14 poorly diﬀerentiated nonsmall-cell lung cancer,
and 13 other malignancies (2 mixed adenocarcinomas and
neuroendocrine, 2 adenoid cystic carcinomas, 1 pleomor-
phic carcinoma, 1 sarcomatoid carcinoma, 1 nonspeciﬁc
CTM, 3 epithelioid mesotheliomas, 1 poorly diﬀerentiated
epithelioid neoplasm, 1 mesenchymal neuron neoplasm, and
1 sarcoma). EBUS-TBNA revealed a nonmalignant diagnosis
in 25 cases: 5 hamartomas, 4 ﬁbrotic lesions after radiotherapy,
6 bronchogenic cyst, 1 pericardial cyst, 1 benign leiomyoma,
5 pneumonias, 1 mycetoma and 2 cases of granulomatosis
(1sarcoidosis and 1 tuberculosis). In this group of patients,
sensitivity, negative predictive value, and diagnostic accuracy
were 90.9% (95% CI: 86.9–93.8), 51.0% (95% CI: 37.5–64.4),
and 91.7% (95% CI: 88.0–94.4), respectively.
3.5. Group 5: Unknown Origin Lymphadenopathy. +is
group included 152 patients: 59 granulomatosis lymphade-
nitis, 60 reactive lymph nodes, 3 lymphoproliferative disor-
ders, 2 adenocarcinomas, 2 metastasis from other sites
(thyroid and breast), 1 small-cell lung cancer, 1 ectopic
thymus tissue, and 24 false negative samples. Sensitivity,
negative predicted value, and diagnostic accuracy were 25%
(95% CI: 13.3–42.1), 83.3% (95% CI: 76.4–88.5), and 84.2%
(95%CI: 77.6–89.2), respectively.+e diagnostic performance
of EBUS-TBNA in the diﬀerent groups of patients according
to clinical indication for the procedure is shown in Table 4.
4. Discussion
Many literature studies have reported on EBUS-TBNA
experience for mediastinal staging in lung cancer patients
and some have described the utility of EBUS-TBNA in other
pathologies with mediastinal lymphadenopathies such as
sarcoidosis, tuberculosis, and lymphoma [10, 11].
During the last decade, EBUS-TBNA has become an
essential diagnostic procedure in thoracic disease, revolu-
tionizing the approach to diagnosis and treatment and
guiding the best treatment option in a large number of
patients. To date, the procedure has been widely used to
performmediastinal staging and has been included in almost
all guidelines as the preferred ﬁrst approach for invasive
mediastinal staging in lung cancer patients [4, 12].
A recent meta-analysis showed a sensitivity of EBUS-
TBNA for mediastinal staging ranging from 81 to 95% [13].
Likewise, an Italianmulticentre trial published in 2017 analysed
485 patients showing a sensitivity of 90% with a diagnostic
accuracy of 93% [14]. In agreement with these publications, our
study showed an EBUS-TBNA sensitivity formalignant disease
of 90.7% and a diagnostic accuracy of 93.1% in 728 patients in
our Group 1 patients (lung cancer staging). Surprisingly, the
ﬁnal EBUS-TBNA diagnosis was lymphoma in ﬁve patients
with a single pulmonary lesion and mediastinal lymphade-
nopathies highly suspected for lung cancer. EBUS-TBNA
samples were able to subtype the lymphoma in three of the
ﬁve (60%) cases achieving a deﬁnitive diagnosis of Hodgkin’s
lymphoma, classic variation, showing the feasibility of lym-
phoma diagnosis and subclassiﬁcation by EBUS-TBNA
Table 3: Cytological results of EBUS-TBNA.
Cytological results Number of patients
Adenocarcinoma 692
Squamous cell carcinoma 216
Neuroendocrine tumour 143
SCLC 102
Large-cell neuroendocrine tumour 19
Mixed large- and small-cell
neuroendocrine 9
Typical carcinoid 10
Atypical carcinoid 3
Metastasis from extrathoracic malignancy 154
NSCLC poorly diﬀerentiated (NAS) 65
Lymphoproliferative disorders 24
Other nonneoplastic diagnosis 28
Lymphadenitis granulomatosis 100
Sarcoid-like granulomas 97
Tuberculosis 3
Other malignancies∗ 34
Reactive/normal lymph nodes 316∗Other malignancies included 1 thymoma, 8 mesothelioma, 3 adenoid
cystic carcinoma, 6 mixed tumours, 9 poorly diﬀerentiated epithelial tu-
mours of unknown origin, 1 sarcoma, and 3 sarcomatoid carcinoma.
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samples even if the need for further histological evaluation
remains essential in many cases [15, 16]. In the subgroup of
patients who underwent EBUS-TBNA for restaging the me-
diastinum after neoadjuvant chemotherapy, there were a rela-
tive higher incidence of inadequate samples due to the presence
of ﬁbrosis in the mediastinum and the diﬃculty of the pro-
cedure specially after chemoradiotherapy.
Considering our Group 2 (pathological diagnosis and
mutational status in advanced stage lung cancer), EBUS-
TBNA sensitivity and diagnostic accuracy were both 98.5%.
EBUS-TBNA also provided adequate material for molecular
analysis whenever requested in advanced stage adenocar-
cinomas in 98% of cases. +is datum conﬁrms our previous
published experience of molecular analysis with EBUS-
TBNA specimens where we showed a sensitivity of 96.9%
[17]. Our previous study also demonstrated that molecular
analysis obtained from EBUS-TBNA specimens was equiv-
alent to that obtained from surgical specimens, with no
diﬀerences in terms of sensitivity and diagnostic accuracy [17].
Due to the low invasive and the feasibility of repeated
procedures, EBUS-TBNA is the ideal procedure to establish
a cell-type diagnosis and to provide adequate specimens for
molecular assay in advanced lung cancer patients. +e
procedure’s high accuracy and low risk of complications
make it suitable for low performance status patients who
could still beneﬁt from targeted therapy [18].
In Group 3 (lymphadenopathy in previous malignancy),
EBUS-TBNA showed a sensitivity and diagnostic accuracy
of 92.4% and 94.7%, respectively, in agreement with a pre-
vious similar study published by Navani et al. and also with
our previous reported experience in this subset of patients
[8, 9]. In this group of patients, EBUS-TBNA was a crucial
diagnostic approach. +e results of this study showed that
35.3% of patients with lymphadenopathy suspected for a re-
currence did not really have a recurrence, and EBUS-TBNA
revealed a diﬀerent diagnosis. From all nonmalignant di-
agnoses, lymphadenitis granulomatosis was found in 36% of
patients. EBUS-TBNA specimens provided adequate di-
agnosis avoiding unnecessary treatments in cases of non-
malignant disease and guiding therapy in cases of recurrence.
In the diagnosis of Group 4 patients (pulmonary le-
sions), EBUS-TBNA demonstrated a sensitivity and accu-
racy of 90.9% and 91.7%, respectively, in line with Nakajima
et al.’s published data (sensitivity of 94.1% and diagnostic
accuracy of 94.3% in the diagnosis of peribronchial and
peritracheal lesions) [19]. Clinical presentations vary widely
in this group, and EBUS-TBNA was able to establish
a correct diagnosis in the vast majority of cases also in
nonmalignant intrapulmonary lesions. Some interesting
ﬁndings in this group included the diagnosis of a benign
leiomyoma, a mycetoma, and ectopic thymus tissue.
In the investigation of Group 5 (unknown origin
lymphadenopathy), EBUS-TBNA presented a diagnostic
accuracy of 84.2%. Due to the very low prevalence of malig-
nancy in this group of patients, sensitivity was not surprisingly
very low (25%). +e vast majority of patients in this group had
an inﬂammatory disease with the most frequent diagnosis of
granulomatous lymphadenitis compatible with sarcoidosis.
Our results refer to the largest published series in EBUS-
TBNA, in a high-volume thoracic oncology institution,
demonstrating the utility and high accuracy of EBUS-TBNA
in diﬀerent clinical scenarios in daily clinical practice.
Some additional ﬁndings have also emerged from this
study. First, our study showed a wide use of EBUS-TBNA in
elderly patients (732 patients over 70 years old and 120 over
80 years old), with a very low rate (0.74%) of postprocedure
minor complications and no major events. Other interesting
ﬁndings included the possibility to repeat biopsies easily and
safely, obtaining tumour specimens for genetic assessment
in stage IV NSCLC patients and in other tumour recurrences
without the need for further more invasive procedures.
+ese aspects highlight the importance of EBUS-TBNA as
a diagnostic approach in diﬀerent thoracic oncology sce-
narios, underpinning modern oncological strategy also for
fragile patients and thereby avoiding more invasive and
demanding procedures.
An essential aspect to achieve optimal results is the
specimen handling in EBUS-TBNA [5]. +e use of ROSE
and synergy with the pathologist is crucial during the
procedure both to obtain the best specimen collection and to
achieve all pathological, immunohistochemistry, and mo-
lecular analyses. Despite some diﬀerent previous points of
view regarding ROSE [20–22], a recent metaexpert panel
review showed that ROSE is necessary to reach all molecular
analyses and to prevent invasive surgical procedures after
EBUS-TBNA [23].
Our study has some limitations. +e ﬁrst is its retro-
spective nature, which probably limits and inﬂuences all of
Table 4: Diagnostic performance of EBUS in the diﬀerent groups.
EBUS Overall Group 1 Group 2 Group 3 Group 4 Group 5
Total 1891 728 401 320 290 152
True negative 441 193 6 97 25 120
False negative 121 50 6 17 24 24
True positive 1329 485 389 206 241 8
Performance % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Sensitivity 91.7 (90.1–93.0) 90.7 (87.9–92.8) 98.5 (96.7–99.3) 92.4 (88.1–95.2) 90.9 (86.9–93.8) 25.0 (13.3–42.1)
Speciﬁcity 100 (99.1–100) 100 (98.0–100) 100 (61.0–100) 100 (96.2–100) 100 (86.7–100) 100 (96.9–100)
PPV 100 (99.7–100) 100 (99.2–100) 100 (99.0–100.) 100 (98.2–100) 100 (98.4–100) 100 (67.6–100)
NPV 78.5 (74.9–81.7) 79.4 (73.9–84.0) 50.0 (25.4–74.6) 85.1 (77.4–90.5) 51.0 (37.5–64.4) 83.3 (76.4–88.5)
Accuracy 93.6 (92.4–94.6) 93.1 (91.1–94.8) 98.5 (96.8–99.3) 94.7 (91.7–96.7) 91.7 (88.0–94.4) 84.2 (77.6–89.2)
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the variables included in the analysis. Another bias is that not
all patients underwent a surgical procedure (mediastinoscopy
or VATS) to conﬁrm negative EBUS-TBNA samples but all
patients had a clinical and radiological follow-up longer than 15
months.
In our experience, EBUS-TBNA is not just a technique,
but a philosophy for the investigation of thoracic disease.
EBUS-TBNA feasibility and optimal results largely depend
on the cytopathology and pulmonologists’ experience but
also the way the procedure is performed. Adequate sedation
and ROSE are crucial and should always be used. In experi-
enced hands, EBUS-TBNA oﬀers everything chest physicians
need for the best medical practice without further invasive
procedures. Surgical procedures are still required in highly
suspicious NSCLC cases when EBUS-TBNA is negative for
malignancy and in some cases for lymphoma subtyping.
In conclusion, EBUS-TBNA represents the best di-
agnostic approach in many diﬀerent clinical scenarios in
high-volume thoracic oncology centres and dictates the
consecutive treatment option in the vast majority of patients.
EBUS-TBNA is useful and accurate in a high percentage of
cases underpinning modern oncological therapy, guiding
the best treatment options in lung cancer and avoiding
useless and invasive procedures in case of benign disease.
Based on our previous expertise, we are developing new
applications for EBUS-TBNA such as a new protocol for
EBUS-TBNA primary lung cancer cell culture and micro-
RNA proﬁle in stage IIIA (pN2) NSCLC patients, testing the
feasibility of a microRNA proﬁle obtained from EBUS-
TBNA [24] and the correlation with the prediction of
chemotherapy response. In addition, new molecular ana-
lyses are being developed, and the correlation between PDL-
1 expression and tumour histology is under evaluation.
Abbreviations
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Endobronchial ultrasound transbronchial
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NSCLC: Nonsmall-cell lung cancer
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VATS: Video-assisted thoracoscopy.
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